Abstract: The present invention relates to an inhibitory agent of membrane fusion between a virus envelope and a cell membrane of a host cell for the virus, wherein the inhibitory agent comprises a serine protease inhibitor, and a therapeutic agent or a therapeutic composition, comprising the inhibitory agent. More specifically, the present invention relates to the inhibitory agent, wherein the serine protease inhibitor is one or more of a compound represented by the following general formula (I) or a salt thereof, or a solvate or hydrate thereof, and a therapeutic agent or a therapeutic composition, comprising the inhibitory agent: wherein R1 represents a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group, a substituted or unsubstituted aromatic hydrocarbon group, or a substituted or unsubstituted aromatic heterocyclic group, each of which may optionally comprise a heteroatom.

Abstract: A novel agent is for treating or preventing a glioma. A marker for malignancy of a brain tumor and a prognostic marker for a brain tumor can be used in a method for determining malignancy of a brain tumor and a method for determining a prognosis for a brain tumor patient. The agent for treating or preventing a glioma can include an HVEM inhibitor as an active ingredient. The marker for malignancy of a brain tumor and the prognostic marker for a brain tumor can each include an HVEM protein or an HVEM gene. The method for determining malignancy of a brain tumor and the method for determining a prognosis for a brain tumor patient can each include measuring an HVEM expression amount in a biological sample of a subject.

Abstract: An aircraft flight control system includes a first actuator attached to a wing main body, a horn arm configured to transmit an output of the first actuator to a control surface, and a second actuator that is a rotary actuator and attached to the control surface. At least one of the first actuator and the second actuator is an electromechanical actuator (EMA). A first end of the horn arm is coupled to an output terminal of the first actuator, and a second end of the horn arm is fixed to an output terminal of the second actuator. The second actuator is attached to the control surface such that a turning axis of the output terminal is parallel to or coincides with a fulcrum axis (hinge line) of the control surface.

Abstract: The present invention relates to novel and excellent small-molecule-compounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.

Abstract: An aircraft flight control system includes a first actuator attached to a wing main body, a horn arm configured to transmit an output of the first actuator to a control surface, and a second actuator that is a rotary actuator and attached to the control surface. At least one of the first actuator and the second actuator is an electromechanical actuator (EMA). A first end of the horn arm is coupled to an output terminal of the first actuator, and a second end of the horn arm is fixed to an output terminal of the second actuator. The second actuator is attached to the control surface such that a turning axis of the output terminal is parallel to or coincides with a fulcrum axis (hinge line) of the control surface.

Abstract: The present invention relates to novel and excellent small-molecule-corn pounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.

Abstract: The combined use of a TGF-? signaling inhibitor and an antitumor active substance or an imaging agent modified by a drug-encapsulating macromolecular micelle, or the like, is provided. The selective delivery capability of the antitumor active substance or the imaging agent to the target is improved, increasing the antitumoral activity in the target.

Abstract: A promoter for differentiation of brain tumor initiating cells is provided.

Abstract: A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-?-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.

Abstract: The invention relates to the molecule referred to as ALK-1, and its role as a type I receptor for members of the TGF-? family. The molecule has a role in the phosphorylation of Smad-5 and Smad1, which also act as activators of certain genes. Aspects of the invention relate to this interaction.

Abstract: A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-beta-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.

Abstract: A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-?-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.

Abstract: The invention relates to the molecule referred to as ALK-1, and its role as a type I receptor for members of the TGF-? family. The molecule has a role in the phosphorylation of Smad-5 and Smad1, which also act as activators of certain genes. Aspects of the invention relate to this interaction.

Abstract: A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-?-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.

Abstract: The combined use of a TGF-? signaling inhibitor and an antitumor active substance or an imaging agent modified by a drug-encapsulating macromolecular micelle, or the like, is provided. The selective delivery capability of the antitumor active substance or the imaging agent to the target is improved, increasing the antitumoral activity in the target.

Abstract: The invention includes nucleic acids encoding the Smad6 protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.

Abstract: The invention relates to the molecule referred to as ALK-1, and its role as a type I receptor for members of the TGF-? family. The molecule has a role in the phosphorylation of Smad-5 and Smad1, which also act as activators of certain genes. Aspects of the invention relate to this interaction.

Abstract: It is an object of the present invention to provide an excellent enhancer for an osteogenesis accelerator that can enhance the activity of BMP as an osteogenesis accelerator. Another object of the present invention is to provide a method of screening for a novel enhancer for an osteogenesis accelerator. The present invention relates to an enhancer for an osteogenesis accelerator, which comprises a compound having a TGF-? selective inhibitory activity as an active ingredient, the enhancer being administered with an osteogenesis accelerator containing BMP as an active ingredient either simultaneously or sequentially, and to a method of screening for an enhancer for an osteogenesis accelerator, comprising using a TGF-? inhibition as a measure for discovering the enhancer.

Abstract: A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-beta-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.

Abstract: It is an object of the present invention to provide an excellent enhancer for an osteogenesis accelerator that can enhance the activity of BMP as an osteogenesis accelerator. Another object of the present invention is to provide a method of screening for a novel enhancer for an osteogenesis accelerator. The present invention relates to an enhancer for an osteogenesis accelerator, which comprises a compound having a TGF-? selective inhibitory activity as an active ingredient, the enhancer being administered with an osteogenesis accelerator containing BMP as an active ingredient either simultaneously or sequentially, and to a method of screening for an enhancer for an osteogenesis accelerator, comprising using a TGF-? inhibition as a measure for discovering the enhancer.